Eli Lilly and Co (MIL:1LLY)
€ 733.1 -11.4 (-1.53%) Market Cap: 703.72 Bil Enterprise Value: 729.10 Bil PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 66/100

Eli Lilly and Co Diabetes & Obesity Update at ADA Call Transcript

Jun 07, 2022 / 03:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the ADA Investor Update. (Operator Instructions) As a reminder, today's conference is being recorded.

And I would now like to turn the conference over to our host, Lauren Zierke. Please go ahead.

Lauren Zierke;Senior Director of Investor Relations

Good morning. Thank you for joining us for Eli Lilly and Company's Obesity & Diabetes Update at ADA. I'm Lauren Zierke, Senior Director of Investor Relations. Joining me on today's call are Mike Mason, President of Lilly Diabetes; Dr. Dan Skovronsky, Chief Scientific and Medical Officer; Dr. Jeff Emmick, Vice President of Diabetes Product Development; Dr. Ruth Gimeno, Vice President of Diabetes Research and Clinical Investigation; and Jamie Croaning, Global Development Leader for Tirzepatide.

During this conference, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on Slide 2. Additional

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot